Pharmaceutical products

Contract Value:: -
Notice Type:: Contract award notice

Published Date:: 01 March 2022
Closing Date:

Location(s):: UK UNITED KINGDOM; UKD NORTH WEST (ENGLAND) (UK UNITED KINGDOM)

Description:

NHS Framework for the North of England, Branded Medicine

HS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)

CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B

CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche

CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months.

CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London

CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 18 months.

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.

Awarded to:: NHS Framework for the North of England, Branded Medicines -Tranche B; Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Accord-UK Ltd, Devon (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Accord-UK Ltd, Devon (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Accord-UK Ltd, Devon (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Accord-UK Ltd, Devon (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Accord-UK Ltd, Devon (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Accord-UK Ltd, Devon (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Accord-UK Ltd, Devon (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); Accord-UK Ltd, Devon (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); Amgen Ltd, Cambridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Aventis Pharma ltd t/a Sanofi, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Aventis Pharma ltd t/a Sanofi, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Bayer Ltd, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Bayer Ltd, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Bayer Ltd, Reading (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Bayer Ltd, Reading (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Bayer Ltd, Reading (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Biogen, Maidenhead (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Biogen, Maidenhead (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Biogen, Maidenhead (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Biogen, Maidenhead (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); Biogen, Maidenhead (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); Bristol Myers Squibb, Uxbridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Celltrion Healthcare United Kingdom Limited, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); Celltrion Healthcare United Kingdom Limited, Slough (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; CST Pharma Limited, Walsall (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; CST Pharma Limited, Walsall (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; CST Pharma Limited, Walsall (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; CST Pharma Limited, Walsall (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); CST Pharma Limited, Walsall (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); Eli Lilly and Company Ltd, Basingstoke (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); Gedeon Richter UK Ltd, Maida Vale - London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Gilead Sciences Limited, Holborn (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Gilead Sciences Limited, Holborn (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Gilead Sciences Limited, Holborn (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Gilead Sciences Limited, Holborn (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); Gilead Sciences Limited, Holborn (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); GlaxoSmithKline UK Limited, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Ipsen, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Ipsen, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Ipsen, Slough (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Ipsen, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); Ipsen, Slough (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); Janssen-Cilag Ltd, High Wycombe (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Merck Serono Limited, Feltham (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Merck Serono Limited, Feltham (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Serono Limited, Feltham (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Merck Serono Limited, Feltham (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Serono Limited, Feltham (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Merck Sharpe and Dohme (UK) Limited, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Merck Sharpe and Dohme (UK) Limited, London (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Napp Pharmaceuticals Ltd, Cambridge (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Napp Pharmaceuticals Ltd, Cambridge (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Novo Nordisk, Gatwick (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Novo Nordisk, Gatwick (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Novo Nordisk, Gatwick (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Novo Nordisk, Gatwick (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Novo Nordisk, Gatwick (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Pfizer Ltd, Kent (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Pfizer Ltd, Kent (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Pfizer Ltd, Kent (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Pfizer Ltd, Kent (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Pfizer Ltd, Kent (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Pfizer Ltd, Kent (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Pfizer Ltd, Kent (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Pfizer Ltd, Kent (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Roche Products Ltd, Garden City (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Roche Products Ltd, Garden City (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Roche Products Ltd, Garden City (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Roche Products Ltd, Garden City (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Roche Products Ltd, Garden City (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Roche Products Ltd, Garden City (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Roche Products Ltd, Garden City (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); Roche Products Ltd, Garden City (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); Sobi (Swedish Orphan Biovitrum Ltd), Cambridgeshire (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Takeda UK Ltd, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Takeda UK Ltd, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Takeda UK Ltd, London (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Takeda UK Ltd, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Takeda UK Ltd, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Takeda UK Ltd, London (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Takeda UK Ltd, London (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Takeda UK Ltd, London (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Teva UK Limited, Castleford (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Teva UK Limited, Castleford (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Teva UK Limited, Castleford (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; Teva UK Limited, Castleford (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; Teva UK Limited, Castleford (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Teva UK Limited, Castleford (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; Teva UK Limited, Castleford (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); Teva UK Limited, Castleford (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); Thornton and Ross Ltd, Huddersfield (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); UCB Pharma Ltd, Slough (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE; UL Global Pharma, Hertfordshire (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London; UL Global Pharma, Hertfordshire (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; UL Global Pharma, Hertfordshire (UK); NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE; UL Global Pharma, Hertfordshire (UK); NHS Framework for the North of England, Branded Medicines -Tranche B; UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); UL Global Pharma, Hertfordshire (UK); NHS Framework for the NOFE, Branded Medicines-Annual Tranche; Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK); Zentiva Pharma UK Ltd, London (UK)

: Download full details as .pdf

The Buyer:: The NHS Commissioning Board (operating under the name of NHS England)

CPV Code(s):: 33600000 - Pharmaceutical products